checkAd

     137  0 Kommentare Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID - Seite 3



    Sources:
    1. “Nearly One in Five American Adults Who Have Had COVID-19 Still Have “Long COVID,” CDC, June 6, 2022, https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.h ...
    2. “The Economic Cost of Long COVID: An Update,” David M. Cutler, Harvard University, July 22, 2022, https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22. ...


    globenewswire
    0 Follower
    Autor folgen
    Seite 3 von 3

    Verfasst von globenewswire
    Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID - Seite 3 TORONTO, March 27, 2024 (GLOBE NEWSWIRE) - Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs …

    Schreibe Deinen Kommentar

    Disclaimer